GlassScriptPhysician profile
Daniel L Raines
NPI 1316081367
$36,776.08
in general payments reported to CMS, 2019-2025
20 companies · $886 in 2025
The $886 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,277 · 2020: $3,083 · 2021: $1,220 · 2022: $12K · 2023: $12K · 2024: $3,984 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,775 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Travel and Lodging: $2,250 · Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,775.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Travel and Lodging | $2,250.00 |
| Food and Beverage | $1,154.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $17,775.00 | 2022-2025 | Fujifilm |
| Medtronic, INC. | $9,933.52 | 2021-2025 | Pillcam |
| Covidien LP | $6,459.11 | 2019-2020 | |
| Abbvie INC. | $480.87 | 2019-2025 | |
| Pfizer INC. | $433.17 | 2019-2025 | |
| Gilead Sciences, INC. | $339.21 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $326.77 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.61 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $171.07 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $119.76 | 2020-2025 | Sucraid, Sucraid |
| Celgene Corporation | $115.84 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $105.08 | 2022 | |
| Ucb, INC. | $58.29 | 2019-2020 | |
| Daiichi Sankyo INC. | $55.49 | 2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $32.66 | 2024-2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $30.82 | 2024 | |
| Cook Medical LLC | $23.49 | 2024 | Hemospray |
| Biofire Diagnostics, LLC | $22.96 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.92 | 2024 | |
| Aimmune Therapeutics, INC. | $18.44 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Raines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.